Skip to main content
main-content

Expert opinion

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.


Concise and thought-provoking commentary, opinion and analysis from leading rheumatology experts.

Minimizing infection risk with biologic therapy

Elderly woman receiving injection (symbolic image with models)

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Why every rheumatologist should understand the microbiome

Microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

Vaccination in children and adolescents with rheumatic conditions

Child being vaccinated (symbolic image with models)

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

Planning and managing pregnancy in lupus patients

Pregnant woman_doctor with clipboard

Megan Clowse discusses the importance of planning pregnancy in patients with lupus to avoid high-risk pregnancy, and outlines strategies to manage active lupus during pregnancy.

Why depression and anxiety matter in patients with inflammatory arthritis

Depressed person

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Author:
Eoin Feeney

18-10-2018 | Microbiome | Editorial | Article

Why every rheumatologist should understand the microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

Authors:
James T Rosenbaum, Mark J Asquith

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

Author:
NM Wulffraat, AM de Groot, EES Nieuwenhuis

16-10-2018 | Pregnancy | Editorial | Article

Planning and managing pregnancy in lupus patients

Megan Clowse discusses the importance of planning pregnancy in patients with lupus to avoid high-risk pregnancy, and outlines strategies to manage active lupus during pregnancy.

Author:
Megan EB Clowse

10-10-2018 | Mental health | Editorial | Article

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

Author:
Susan Bartlett

27-09-2018 | Fibromyalgia | Editorial | Article

Treatment and outcomes of pediatric fibromyalgia: More than resolving pain

David Sherry discusses various pharmacologic and non-pharmacologic treatments for management of pediatric fibromyalgia, and outlines the impact of an interdisciplinary approach on physical function, mental health and pain outcomes in these patients.

Author:
David Sherry

20-07-2018 | Granulomatosis with polyangiitis | Editorial | Article

The ongoing evolution of remission maintenance strategies for granulomatosis with polyangiitis

Eric J Gapud and Philip Seo summarize the key milestones in management of severe granulomatosis with polyangiitis, and evaluate the possibility of long-term reduced intensity or drug-free remission for some patients.

Authors:
Eric J. Gapud, Philip Seo

22-05-2018 | Gout | Editorial | Article

Audits on gout management: Far from excellence, but working on it

Editorial Board member Fernando Pérez-Ruiz analyzes recent audits on the management of gout in primary and secondary care, and suggests strategies to improve clinical practice.

Author:
Fernando Pérez-Ruiz

22-03-2018 | Biosimilars | Editorial | Article

Biosimilars: The price is not right

Editorial Board member Marc Cohen analyzes the various economic factors influencing the price of biosimilars over recent years in rheumatology, focusing on the United States healthcare system.

Author:
Marc D Cohen

21-02-2018 | Gout | Editorial | Article

Gout therapies and cardiovascular risk

Editorial Board member Fernando Pérez-Ruiz highlights recent clinical trials evaluating the effect of febuxostat on risk of cardiovascular comorbidities, and discusses alternative treatments for gout patients with cardiovascular disease.

Author:
Fernando Pérez-Ruiz
image credits